Report No. 6/2026 Obtaining Information on the Issuance of a GMP Certificate for Bioceltix S.A.

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A. (the “Company”, the “Issuer”), with reference to current report ESPI No. 51/2025 dated 23 December 2025 regarding receipt of the final report from the Chief Pharmaceutical Inspector (Główny Inspektor Farmaceutyczny, “GIF”) confirming the Company’s compliance with Good Manufacturing Practice (“GMP”), hereby announces that on 17 February 2026 […]

Report No. 5/2026 Receipt of the decision on environmental conditions for the investment entitled “Biological Veterinary Medicinal Products Manufacturing Facility”

_MACHINE TRANSLATION_ The Management Board of Bioceltix S.A., with its registered office in Wrocław (the “Company”, the “Issuer”), with reference to ESPI current reports No. 4/2024 dated 7 May 2024 and No. 39/2024 dated 17 December 2024, hereby informs that on 29 January 2026 it received the decision on environmental conditions No. WSR-OS.6220.87.2024.AN dated 29 […]

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.